Background Adults with impaired performance status (PS) often receive immune checkpoint inhibitors (ICIs) for advanced non–small cell lung cancer (NSCLC) despite limited efficacy data and unknown effects on end‐of‐life care. Methods This was a retrospective, single‐site study of 237 patients NSCLC who initiated ICI treatment from 2015 to 2017. Cox regression used compare the overall survival (OS) had PS (≥2) at start those 0 or 1 using regression. Logistic conducted analyze association...

The financial burden experienced by patients with cancer represents a barrier to clinical trial participation, and interventions targeting patients' concerns are needed. We sought assess the impact of an equity intervention on burden.We developed reimburse nonclinical expenses related trials (e.g., travel lodging). From July 2015 2017, we surveyed comparison matched age, sex, type, specific trial, phase. longitudinally assessed trial-related lodging cost concerns, wellbeing [FWB]...

Oral anticancer drugs (OACDs) have become increasingly prevalent over the past decade. OACD prescriptions require coordination between payers and providers, which can delay drug receipt. We examined association insurance type, pursuit of copayment assistance, prior authorization (PA), time to receipt (TTR) for new prescriptions.

PURPOSE: Oral anticancer drug (OACD) prescriptions require extensive coordination between providers and payers, which can delay receipt. Specialty pharmacies facilitate communication multiple entities. In 2018, our cancer center partnered with a freestanding organization to implement hospital-based specialty pharmacy (HB-SP). We evaluated the time receipt (TTR) before after HB-SP implementation. METHODS: Data were prospectively collected on all new OACD for adult oncology patients from...

Since the onset of COVID-19, oncology practices across US have integrated telemedicine (TM) and remote patient monitoring (RPM) into routine care clinical trials. The extent provider experience comfort with TM/RPM in treatment trials, however, is unknown. We surveyed researchers to assess TM/RPM.

Oral anticancer drugs (OACDs) are increasingly prescribed for cancer treatment and require significant coordination of care. Retrospective studies suggest that 10% to 20% OACD prescriptions never received by the patients, but reasons behind this poorly understood.To estimate rate failure receive among patients with examine underlying failure.A prospective cohort study was conducted who were a new from January 1, 2018, December 31, 2019, at an urban academic medical center. Data analysis...

6 Background: The past decade has seen a dramatic increase in the number of Food and Drug Administration approvals oral anti-cancer drugs (OACDs). Most OACD prescriptions require coordination between payers providers, which can delay drug receipt. In May 2021, two bills were introduced US House Representatives (HR 3173 HR 3258) to streamline prior authorization (PA) process. this study, we examined clinical process-related factors associated with PA time receipt (TTR) for patients who...

92 Background: While ARSIs have become a cornerstone in treatment for prostate cancer, nonadherence to these oral medications is common. We investigated the association between patterns of prior chronic conditions with ARSI nonadherence. Methods: In this retrospective cohort study, MarketScan database was searched patients >18 years old cancer claim 1/1/2014 and 12/31/2019 who filled >2 prescriptions 9/1/2013 12/31/2020. Nonadherence 4 (hypertension, hyperlipidemia, diabetes, benign...

e17008 Background: Relugolix is a novel oral GnRH antagonist that now an alternative option for patients with prostate cancer (PC) who require androgen deprivation therapy (ADT). The potential benefits of relugolix include rapid testosterone decline and recovery, administration, possible cardiovascular (CV) benefit compared to traditional agonists. This study examines real-world data on prescribing practices clinical experiences at large, urban academic center. Methods: We conducted...

PURPOSE The past decade has seen an increase in oral anticancer drug (OACD) approvals. Polypharmacy and drug-drug interactions (DDIs) likely contribute to OACD toxicity. We assessed a one-time pharmacist-led video consultation identify DDIs. METHODS conducted single-arm telehealth intervention of 30-minute among patients initiating OACDs. visit focused on identifying polypharmacy Feasibility was defined as ≥50% completion all study interventions. determined the prevalence, characteristics,...

389 Background: Existing research describes a number of barriers limiting cancer clinical trial enrollment, including time constraints and financial burden, particularly among under-represented populations. In this study, we sought to assess the relationship between use remote technology in trials patient interest participation amongst oncology patients at an urban academic medical center. Methods: We administered 60-question, cross-sectional, in-person survey adult with solid tumor or...

104 Background: Existing research describes numerous barriers to care for patients with cancer, including time constraints, cost, and additional health conditions. We sought assess telehealth access experience amongst a diverse patient population at an academic medical center. Methods: administered 60-question, cross-sectional, in-person survey adult diagnosis of solid tumor or hematological malignancy on active treatment Columbia University Irving Medical Center (CUIMC) in New York, NY...

525 Background: Since the onset of COVID-19, oncology practices across U.S. have integrated telemedicine (TM) and remote patient monitoring (RPM) into cancer care. However, future role telehealth in remains unknown. We conducted a survey among diverse group patients to assess their access technology interest using TM/RPM as part routine care clinical trials. Methods: Between March 27 June 21, 2023, we administered person surveys receiving treatment at an academic center New York City....

43 Background: Most oral anti-cancer drugs (OACD) prescriptions require extensive coordination between providers and payers, which can delay drug receipt. Specialty pharmacies are intended to facilitate communication multiple entities deliver OACDs with increased efficiency. In 2018, our cancer center partnered Shields Health Solutions (SHS), a freestanding organization providing care implement hospital-based specialty pharmacy. We evaluated the rate of failed receipt (FR) time (TTR) before...

41 Background: Oral anti-cancer drugs (OACDs) have become increasingly prescribed over the last 10 years and require a significant amount of care coordination. Preliminary administrative database studies shown that 10-15% prescriptions are never received by patient, but reasons behind this poorly understood. In study, we prospectively identified failure to receive (FR) cases in which OACD were patients, examined underlying for FR, assessed clinical process-related factors associated with FR....

49 Background: Immune checkpoint inhibitors (ICI) improve survival for adults with metastatic NSCLC. Despite limited data on ICI efficacy in poor performance status (PS), oncologists often elect to treat this population given their relatively favorable toxicity profile and potential durable response. We aimed describe the timing of patients’ based PS, explore effect late use end-of-life (EOL) care. Methods: Retrospective study 235 NSCLC at a single academic center who initiated from...

385 Background: Since the onset of COVID-19, oncology practices across U.S. have integrated telemedicine (TM) and remote patient monitoring (RPM) into routine care clinical trials. However, extent provider experience comfort with TM/RPM in treatment trials is unknown. In this study, we surveyed researchers to assess TM/RPM. Methods: Between April 10 June 1, 2022, distributed email surveys U.S.-based members American Society Clinical Oncology (ASCO) whose member records indicated an interest...

405 Background: The past decade has seen a dramatic increase in the number oral anti-cancer drug (OACD) approvals U.S. Though polypharmacy and drug-drug interactions (DDIs) likely contribute to OACD toxicity, prevalence of these features patients on OACDs remains largely unknown. We aimed assess feasibility preliminary efficacy one-time 30-minute pharmacist-led video consultation among cancer initiating OACDs. Methods: conducted single-arm, prospective telehealth intervention study...

6566 Background: Cancer patients’ (pts) financial concerns (FCs) represent a barrier to clinical trial (CT) participation and interventions targeting pts’ FCs are needed. We sought assess the impact of an equity intervention on CT FCs. Methods: developed reimburse non-clinical expenses related CTs (e.g. travel, lodging) for low income pts. From 7/2015-7/2017, we surveyed control pts matched by age, sex, cancer type, specific phase. longitudinally assessed (cost CT-related travel lodging),...

10040 Background: As the population ages, it has become increasingly important to understand risks and benefits of novel agents among older adults with cancer. Immunotherapy (IO) revolutionized treatment advanced NSCLC, but less is known about activity PD-(L)1 blockade in (≥70 years). In these pts, immunosenescence may theoretically blunt effectiveness anti-PD-(L)1 therapy and/or alter its toxicity profile. We sought assess impact age on clinical outcomes rates IO-related toxicities pts...

1592 Background: The past decade has seen a dramatic increase in the number of oral anti-cancer drug (OACD) approvals United States. Though polypharmacy and drug-drug interactions (DDIs) likely contribute to OACD toxicity, prevalence these features patients on OACDs remains largely unknown. We aimed evaluate one-time 30-minute pharmacist-led video consultation among metastatic cancer initiating identify medication list inaccuracies as well prevalence, characteristics, severity OACD-related...

94 Background: During the COVID-19 pandemic, remote cancer care, and video communication in particular, has become increasingly common context of routine visits clinical trials. Though this medium potential to augment patient-provider communication, telehealth also raises concerns about digital divide promoting disparities access care. In study, we surveyed oncology patients who declined participate a pilot study looking at one-time pharmacist-led visit for initiating oral anti-cancer...